drugset / Trial / NCT04415918
Bezlotoxumab Efficacy and Tolerability in Cancer Patient
Non-randomizedSingle-groupOpen-labelPrevention
Summary
Investigation of efficacy and tolerability of bezlotoxumab in patients with cancer diagnosis in terms of preventing CDI recurrence.
Timeline
- Start
- 2020-07-01
- Primary completion
- 2021-07-01
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bezlotoxumab | Monoclonal antibody | 10 mg/kg | Intravenous |